The most important finding of the present study is that, for MSI-H GC patients, EMAST+ tumors were associated with more favorable clinicopathological features, a better prognosis, and a higher frequency of genetic mutations in MSH2, AXIN1, and POLD1 compared with EMAST− tumors. The gene discussed is POLD1; the disease is gastric cancer.